Phase 2 Study of Chidamide for MRD-Positive DLBCL in First Complete Remission
A phase 2 study is underway to assess chidamide maintenance therapy in adults with MRD-positive DLBCL post-complete response.
Asset / Drug
Drug and asset intelligence for Chidamide with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.